The Antibodies Contract Manufacturing Market is driven by growing demand for monoclonal antibodies.
The antibodies contract manufacturing market involves the production of monoclonal antibodies through various steps including cell line development, cell culture, purification, and analytical testing. Monoclonal antibodies have wide applications across various therapeutic areas such as oncology, immunology, ophthalmology, infectious diseases and others. They are popular for their high specificity and affinity in targeting proteins associated with various diseases. The contract manufacturing outsourcing model helps pharmaceutical companies focus on drug discovery and clinical trials while manufacturers handle production. This provides cost savings to drug developers along with speed to market advantages.
The global antibodies contract manufacturing market is estimated to be valued at USD 19.61 Bn in 2024 and is expected to reach USD 38.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10% from 2024 to 2031.
Key Takeaways
Key players operating in the antibodies contract manufacturing market are Lonza Group, WuXi Biologics, Catalent, Inc., Fujifilm Diosynth Biotechnologies, Rentschler Biopharma SE, Charles River Laboratories, Samsung Biologics, AbbVie Contract Manufacturing, and Avid Bioservices, Inc.
The Antibodies Contract Manufacturing Market Trends for monoclonal antibodies is growing rapidly driven by their increasing applications across variou
The antibodies contract manufacturing market involves the production of monoclonal antibodies through various steps including cell line development, cell culture, purification, and analytical testing. Monoclonal antibodies have wide applications across various therapeutic areas such as oncology, immunology, ophthalmology, infectious diseases and others. They are popular for their high specificity and affinity in targeting proteins associated with various diseases. The contract manufacturing outsourcing model helps pharmaceutical companies focus on drug discovery and clinical trials while manufacturers handle production. This provides cost savings to drug developers along with speed to market advantages.
The global antibodies contract manufacturing market is estimated to be valued at USD 19.61 Bn in 2024 and is expected to reach USD 38.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 10% from 2024 to 2031.
Key Takeaways
Key players operating in the antibodies contract manufacturing market are Lonza Group, WuXi Biologics, Catalent, Inc., Fujifilm Diosynth Biotechnologies, Rentschler Biopharma SE, Charles River Laboratories, Samsung Biologics, AbbVie Contract Manufacturing, and Avid Bioservices, Inc.
The Antibodies Contract Manufacturing Market Trends for monoclonal antibodies is growing rapidly driven by their increasing applications across variou
7 days ago
